Varicella zoster virus in solid organ transplantation

American Journal of Transplantation

Volumn 13, Issue SUPPL.4, 2013, Pages 138-146

  Pergam, S A ^a,b,c   Limaye, A P ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Vaccine and Infectious Disease Institute   (United States)

^c USA   (United States)

Author keywords

Herpes zoster; transplantation; varicella

Indexed keywords

ACICLOVIR; CHICKENPOX VACCINE; FAMCICLOVIR; HERPES ZOSTER IMMUNOGLOBULIN; IMMUNOGLOBULIN; VALACICLOVIR; VARICELLA ZOSTER VACCINE;

ANTIVIRAL THERAPY; ARTICLE; CHICKENPOX; DISEASE COURSE; FEVER; FLUORESCENT ANTIBODY TECHNIQUE; HERPES ZOSTER; HUMAN; IMMUNIZATION; INCUBATION TIME; INFECTION CONTROL; LABORATORY TEST; MORBIDITY; ORGAN TRANSPLANTATION; POLYMERASE CHAIN REACTION; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; PRURITUS; RASH; RISK FACTOR; SOLID ORGAN TRANSPLANTATION; VARICELLA ZOSTER VIRUS;

EID: 84874845641     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12107     Document Type: Article

References (91)

1. Gnann JW, Jr., Whitley RJ,. Clinical practice. Herpes zoster. N Engl J Med 2002; 347: 340-346.
2. Sawyer MH, Chamberlin CJ, Wu YN, Aintablian N, Wallace MR,. Detection of varicella-zoster virus DNA in air samples from hospital rooms. J Infect Dis 1994; 169: 91-94.
3. Marin M, Guris D, Chaves SS, Schmid S, Seward JF,. Prevention of varicella: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56: 1-40.
4. Heininger U, Seward JF,. Varicella. Lancet 2006; 368: 1365-1376.
5. Nguyen HQ, Jumaan AO, Seward JF,. Decline in mortality due to varicella after implementation of varicella vaccination in the United States. N Engl J Med 2005; 352: 450-458.
6. Davis MM, Patel MS, Gebremariam A,. Decline in varicella-related hospitalizations and expenditures for children and adults after introduction of varicella vaccine in the United States. Pediatrics 2004; 114: 786-792.
7. Gilden DH, Kleinschmidt-DeMasters BK, LaGuardia JJ, Mahalingam R, Cohrs RJ,. Neurologic complications of the reactivation of varicella-zoster virus. N Engl J Med 2000; 342: 635-645.
8. Straus SE, Ostrove JM, Inchauspe G, Felser JM, Freifeld A, Croen KD, Sawyer MH,. NIH conference. Varicella-zoster virus infections. Biology, natural history, treatment, and prevention. Ann Intern Med 1988; 108: 221-237.
9. Johnson RW,. The future of predictors, prevention, and therapy in postherpetic neuralgia. Neurology 1995; 45: S70-S72.
10. Crespo JF, Gorriz JL, Avila A, et al. Prevalence of past varicella zoster virus infection in candidates for kidney transplantation: Vaccination in seronegative patients. Transplant Proc 2002; 34: 77.
11. Geel AL, Landman TS, Kal JA, van Doomum GJ, Weimar W,. Varicella zoster virus serostatus before and after kidney transplantation, and vaccination of adult kidney transplant candidates. Transplant Proc 2006; 38: 3418-3419.
12. Pandya A, Wasfy S, Hebert D, Allen UD,. Varicella-zoster infection in pediatric solid-organ transplant recipients: A hospital-based study in the prevaricella vaccine era. Pediatr Transplant 2001; 5: 153-159.
13. Furth SL, Sullivan EK, Neu AM, Tejani A, Fivush BA,. Varicella in the first year after renal transplantation: A report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Pediatr Transplant 1997; 1: 37-42.
14. Rodriguez-Moreno A, Sanchez-Fructuoso AI, Calvo N, et al. Varicella infection in adult renal allograft recipients: Experience at one center. Transplant Proc 2006; 38: 2416-2418.
15. Fehr T, Bossart W, Wahl C, Binswanger U,. Disseminated varicella infection in adult renal allograft recipients: Four cases and a review of the literature. Transplantation 2002; 73: 608-611.
16. Feldhoff CM, Balfour HH, Jr., Simmons RL, Najarian JS, Mauer SM,. Varicella in children with renal transplants. J Pediatr 1981; 98: 25-31.
17. McGregor RS, Zitelli BJ, Urbach AH, Malatack JJ, Gartner JC, Jr., Varicella in pediatric orthotopic liver transplant recipients. Pediatrics 1989; 83: 256-261.
18. Arness T, Pedersen R, Dierkhising R, Kremers W, Patel R,. Varicella zoster virus-associated disease in adult kidney transplant recipients: Incidence and risk-factor analysis. Transpl Infect Dis 2008; 10: 260-268.
19. Gourishankar S, McDermid JC, Jhangri GS, Preiksaitis JK,. Herpes zoster infection following solid organ transplantation: Incidence, risk factors and outcomes in the current immunosuppressive era. Am J Transplant 2004; 4: 108-115.
20. Pergam SA, Forsberg CW, Boeckh MJ, et al. Herpes zoster incidence in a multicenter cohort of solid organ transplant recipients. Transpl Infect Dis 2011; 13: 15-23.
21. Koc Y, Miller KB, Schenkein DP, et al. Varicella zoster virus infections following allogeneic bone marrow transplantation: Frequency, risk factors, and clinical outcome. Biol Blood Marrow Transplant 2000; 6: 44-49.
22. Lauzurica R, Bayes B, Frias C, et al. Disseminated varicella infection in adult renal allograft recipients: Role of mycophenolate mofetil. Transplant Proc 2003; 35: 1758-1759.
23. Geel A, Zuidema W, van Gelder T, van Doornum G, Weimar W,. Successful vaccination against varicella zoster virus prior to kidney transplantation. Transplant Proc 2005; 37: 952-953.
24. Fall AJ, Aitchison JD, Krause A, Hasan A, Hamilton JR, Gould FK,. Donor organ transmission of varicella zoster due to cardiac transplantation. Transplantation 2000; 70: 211-213.
25. Watson BM, Piercy SA, Plotkin SA, Starr SE,. Modified chickenpox in children immunized with the Oka/Merck varicella vaccine. Pediatrics 1993; 91: 17-22.
26. Chaves SS, Zhang J, Civen R, et al. Varicella disease among vaccinated persons: Clinical and epidemiological characteristics, 1997-2005. J Infect Dis 2008; 197 (Suppl 2): S127-S131.
27. Fuks L, Shitrit D, Fox BD, Amital A, Raviv Y, Bakal I, Kramer MR,. Herpes zoster after lung transplantation: Incidence, timing, and outcome. Ann Thorac Surg 2009; 87: 423-426.
28. Manuel O, Kumar D, Singer LG, Cobos I, Humar A,. Incidence and clinical characteristics of herpes zoster after lung transplantation. J Heart Lung Transplant 2008; 27: 11-16.
29. Satoh S, Tada H, Murakami M, et al. The influence of mycophenolate mofetil versus azathioprine and mycophenolic acid pharmacokinetics on the incidence of acute rejection and infectious complications after renal transplantation. Transplant Proc 2005; 37: 1751-1753.
30. Triemer HL, Pearson TC, Odom KL, Larsen CP,. Analysis of a single-center experience with mycophenolate mofetil based immunosuppression in renal transplantation. Clin Transplant 2000; 14: 413-420.
31. Civen R, Chaves SS, Jumaan A, et al. The incidence and clinical characteristics of herpes zoster among children and adolescents after implementation of varicella vaccination. Pediatr Infect Dis J 2009; 28: 954-959.
32. Volpi A,. Severe complications of herpes zoster. Herpes 2007; 14 (Suppl 2): 35-39.
33. Gnann JW, Jr., Varicella-zoster virus: Atypical presentations and unusual complications. J Infect Dis 2002; 186 (Suppl 1): S91-S98.
34. Alvite-Canosa M, Paniagua-Martin MJ, Quintela-Fandino J, Otero A, Crespo-Leiro MG,. Fulminant hepatic failure due to varicella zoster in a heart transplant patient: Successful liver transplant. J Heart Lung Transplant 2009; 28: 1215-1216.
35. Oh KH, Ahn C, Kim YS, et al. Atypical generalized zoster with suspicious esophageal involvement and early relapse in an adult renal transplant recepient. Transplant Proc 2002; 34: 1174-1177.
36. Hovens MM, Vaessen N, Sijpkens YW, de Fijter JW,. Unusual presentation of central nervous system manifestations of Varicella zoster virus vasculopathy in renal transplant recipients. Transpl Infect Dis 2007; 9: 237-240.
37. Verleden GM, Vos R, Van Raemdonck DE, Laleman W, Vanaudenaerde BM,. Acute liver failure due to varicella zoster virus infection after lung transplantation: A case report. Transplant Proc 2012; 44: 1457-1459.
38. Assi M, Abou Antoun S,. Unusual neurologic manifestations of varicella zoster virus infection with the absence of rash in a kidney transplant recipient. Transpl Infect Dis 2011; 13: 545-547.
39. American Academy of Pediatrics. Varicella-Zoster Infections. In:, Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds. Red Book 2012: Report of the Committee on Infectious Diseases, 29th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2012; pages 774-789; 841-847.
40. Taha YA, Quinlivan M, Scott FT, et al. Are false negative direct immnufluorescence assays caused by varicella zoster virus gE mutant strains ? J Med Virol 2004; 73: 631-635.
41. Coffin SE, Hodinka RL,. Utility of direct immunofluorescence and virus culture for detection of varicella-zoster virus in skin lesions. J Clin Microbiol 1995; 33: 2792-2795.
42. Breuer J, Schmid DS, Gershon AA,. Use and limitations of varicella-zoster virus-specific serological testing to evaluate breakthrough disease in vaccinees and to screen for susceptibility to varicella. J Infect Dis 2008; 197 (Suppl 2): S147-S151.
43. Brunell PA, Wood D,. Varicella serological status of healthcare workers as a guide to whom to test or immunize. Infect Control Hosp Epidemiol 1999; 20: 355-357.
44. Balfour HH, Jr., McMonigal KA, Bean B,. Acyclovir therapy of varicella-zoster virus infections in immunocompromised patients. J Antimicrob Chemother 1983; 12 (Suppl B): 169-179.
45. Carcao MD, Lau RC, Gupta A, Huerter H, Koren G, King SM,. Sequential use of intravenous and oral acyclovir in the therapy of varicella in immunocompromised children. Pediatr Infect Dis J 1998; 17: 626-631.
46. Shepp DH, Dandliker PS, Meyers JD,. Treatment of varicella-zoster virus infection in severely immunocompromised patients. A randomized comparison of acyclovir and vidarabine. N Engl J Med 1986; 314: 208-212.
47. Sulliger JM, Imbach P, Barandun S, et al. Varicella and herpes zoster in immunosuppressed children: Preliminary results of treatment with intravenous immunoglobulin. Helv Paediatr Acta 1984; 39: 63-70.
48. Vales-Albertos LJ, Andrade-Sierra J, Gomez-Navarro B, et al. Nonspecific immunoglobulin and granulocyte-macrophage colony-stimulating factor use in complicated varicella zoster: The first case report in a renal transplant recipient. Transplantation 2006; 81: 809-810.
49. Kashtan CE, Cook M, Chavers BM, Mauer SM, Nevins TE,. Outcome of chickenpox in 66 pediatric renal transplant recipients. J Pediatr 1997; 131: 874-877.
50. Prelog M, Schonlaub J, Zimmerhackl LB,. Aciclovir and varicella-zoster-immunoglobulin in solid-organ transplant recipients. Pediatr Nephrol 2011; 26: 663-673.
51. Tyring S, Belanger R, Bezwoda W, Ljungman P, Boon R, Saltzman RL,. A randomized, double-blind trial of famciclovir versus acyclovir for the treatment of localized dermatomal herpes zoster in immunocompromised patients. Cancer Invest 2001; 19: 13-22.
52. Arora A, Mendoza N, Brantley J, Yates B, Dix L, Tyring S,. Double-blind study comparing 2 dosages of valacyclovir hydrochloride for the treatment of uncomplicated herpes zoster in immunocompromised patients 18 years of age and older. J Infect Dis 2008; 197: 1289-1295.
53. Otsuki K, Kenmochi T, Maruyama M, et al. A case of Ramsay Hunt syndrome in living-kidney transplant recipient. Transplant Proc 2012; 44: 307-308.
54. Erard V, Guthrie KA, Varley C, et al. One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: No evidence of rebound varicella-zoster virus disease after drug discontinuation. Blood 2007; 110: 3071-3077.
55. Lowance D, Neumayer HH, Legendre CM, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med 1999; 340: 1462-1470.
56. Gane E, Saliba F, Valdecasas GJ, et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected]. Lancet 1997; 350: 1729-1733.
57. Humar A,. Reactivation of viruses in solid organ transplant patients receiving cytomegalovirus prophylaxis. Transplantation 2006; 82: S9-S14.
58. Fiddian P, Sabin CA, Griffiths PD,. Valacyclovir provides optimum acyclovir exposure for prevention of cytomegalovirus and related outcomes after organ transplantation. J Infect Dis 2002; 186 (Suppl 1): S110-S115.
59. Furth SL, Hogg RJ, Tarver J, Moulton LH, Chan C, Fivush BA,. Varicella vaccination in children with chronic renal failure. A report of the Southwest Pediatric Nephrology Study Group. Pediatr Nephrol 2003; 18: 33-38.
60. Webb NJ, Fitzpatrick MM, Hughes DA, et al. Immunisation against varicella in end stage and pre-end stage renal failure. Trans-Pennine Paediatric Nephrology Study Group. Arch Dis Child 2000; 82: 141-143.
61. Broyer M, Tete MJ, Guest G, Gagnadoux MF, Rouzioux C,. Varicella and zoster in children after kidney transplantation: Long-term results of vaccination. Pediatrics 1997; 99: 35-39.
62. Kano H, Mizuta K, Sakakihara Y, et al. Efficacy and safety of immunization for pre- and post-liver transplant children. Transplantation 2002; 74: 543-550.
63. Nithichaiyo C, Chongsrisawat V, Hutagalung Y, Bock HL, Poovorawa Y,. Immunogenicity and adverse effects of live attenuated varicella vaccine (Oka-strain) in children with chronic liver disease. Asian Pac J Allergy Immunol 2001; 19: 101-105.
64. Barton M, Wasfy S, Melbourne T, et al. Sustainability of humoral responses to varicella vaccine in pediatric transplant recipients following a pretransplantation immunization strategy. Pediatr Transplant 2009; 13: 1007-1013.
65. Benden C, Danziger-Isakov LA, Astor T, et al. Variability in immunization guidelines in children before and after lung transplantation. Pediatr Transplant 2007; 11: 882-887.
66. Levin MJ,. Varicella vaccination of immunocompromised children. J Infect Dis 2008; 197 (Suppl 2): S200-S206.
67. Burroughs M, Moscona A,. Immunization of pediatric solid organ transplant candidates and recipients. Clin Infect Dis 2000; 30: 857-869.
68. Khan S, Erlichman J, Rand EB,. Live virus immunization after orthotopic liver transplantation. Pediatr Transplant 2006; 10: 78-82.
69. Weinberg A, Horslen SP, Kaufman SS, et al. Safety and immunogenicity of varicella-zoster virus vaccine in pediatric liver and intestine transplant recipients. Am J Transplant 2006; 6: 565-568.
70. Zamora I, Simon JM, Da Silva ME, Piqueras AI,. Attenuated varicella virus vaccine in children with renal transplants. Pediatr Nephrol 1994; 8: 190-192.
71. Chaves Tdo S, Lopes MH, de Souza VA, et al. Seroprevalence of antibodies against varicella-zoster virus and response to the varicella vaccine in pediatric renal transplant patients. Pediatr Transplant 2005; 9: 192-196.
72. Josephson A, Gombert ME,. Airborne transmission of nosocomial varicella from localized zoster. J Infect Dis 1988; 158: 238-241.
73. Lopez AS, Burnett-Hartman A, Nambiar R, et al. Transmission of a newly characterized strain of varicella-zoster virus from a patient with herpes zoster in a long-term-care facility, West Virginia, 2004. J Infect Dis 2008; 197: 646-653.
74. Harpaz R, Ortega-Sanchez IR, Seward JF,. Prevention of herpes zoster: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008; 57: 1-30.
75. A new product (VariZIG) for postexposure prophylaxis of varicella available under an investigational new drug application expanded access protocol. MMWR Morb Mortal Wkly Rep 2006; 55: 209-210.
76. FDA approval of an extended period for administering VariZIG for postexposure prophylaxis of varicella. MMWR Morb Mortal Wkly Rep 2012; 61: 212.
77. Zaia JA, Levin MJ, Preblud SR, Leszczynski J, et al. Evaluation of varicella-zoster immune globulin: Protection of immunosuppressed children after household exposure to varicella. J Infect Dis 1983; 147: 737-743.
78. Orenstein WA, Heymann DL, Ellis RJ, et al. Prophylaxis of varicella in high-risk children: Dose-response effect of zoster immune globulin. J Pediatr 1981; 98: 368-373.
79. Hanngren K, Falksveden L, Grandien M, Lidin-Janson G,. Zoster immunoglobulin in varicella prophylaxis. A study among high-risk patients. Scand J Infect Dis 1983; 15: 327-334.
80. Suga S, Yoshikawa T, Ozaki T, Asano Y,. Effect of oral acyclovir against primary and secondary viraemia in incubation period of varicella. Arch Dis Child 1993; 69: 639-642; discussion 642-633.
81. Goldstein SL, Somers MJ, Lande MB, Brewer ED, Jabs KL,. Acyclovir prophylaxis of varicella in children with renal disease receiving steroids. Pediatr Nephrol 2000; 14: 305-308.
82. Amini H, Javan M, Gazerani P, Ghaffari A, Ahmadiani A,. Lack of bioequivalence between two aciclovir tablets in healthy subjects. Clin Drug Investig 2008; 28: 47-53.
83. de Miranda P, Blum MR,. Pharmacokinetics of acyclovir after intravenous and oral administration. J Antimicrob Chemother 1983; 12 (Suppl B): 29-37.
84. Hoglund M, Ljungman P, Weller S,. Comparable aciclovir exposures produced by oral valaciclovir and intravenous aciclovir in immunocompromised cancer patients. J Antimicrob Chemother 2001; 47: 855-861.
85. Boeckh M,. Prevention of VZV infection in immunosuppressed patients using antiviral agents. Herpes 2006; 13: 60-65.
86. Weinstock DM, Boeckh M, Boulad F, et al. Postexposure prophylaxis against varicella-zoster virus infection among recipients of hematopoietic stem cell transplant: Unresolved issues. Infect Control Hosp Epidemiol 2004; 25: 603-608.
87. American Academy of Pediatrics Committee on Infectious Diseases: The use of oral acyclovir in otherwise healthy children with varicella. Pediatrics 1993; 91: 674-676.
88. Seward JF, Zhang JX, Maupin TJ, Mascola L, Jumaan AO,. Contagiousness of varicella in vaccinated cases: A household contact study. JAMA 2004; 292: 704-708.
89. Zostavax in renal transplant patients. ClinicalTrials.gov Identifier NCT01137669, accessed from ClinicalTrials. gov June 2012.
90. Safety and immunogenicity of zostavax vaccine in patients undergoing living donor kidney transplantation. ClinicalTrials.gov Identifier NCT00940940. Accessed from ClinicalTrials.gov on June 2012.
91. Hata A, Asanuma H, Rinki M, et al. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med 2002; 347: 26-34.